Cutaneous Comorbidities Associated With Atopic Dermatitis in Israel: A Retrospective Real-World Data Analysis

被引:4
作者
Leshem, Yael A. A. [1 ,2 ]
Sugerman, Philip B. B. [3 ]
Weil, Clara [4 ]
Chodick, Gabriel [2 ]
Liang, Huifang [3 ]
Wang, Hongwei [3 ]
Calimlim, Brian [3 ]
Dorfman, Ana [5 ]
Shalev, Varda [2 ,4 ]
Ben Amitai, Dan [2 ,6 ]
机构
[1] Rabin Med Ctr, Div Dermatol, Zeev Jabotinsky St 39, IL-49100 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[3] AbbVie Inc, N Chicago, IL USA
[4] Maccabi Healthcare Serv, Maccabi Inst Res & Innovat Maccabitech, Tel Aviv, Israel
[5] AbbVie Biopharmaceut Ltd, Hod Hasharon, Israel
[6] Schneider Childrens Med Ctr Israel, Pediat Dermatol, Petah Tiqwa, Israel
关键词
QUALITY-OF-LIFE; UNITED-STATES; HAND ECZEMA; NATIONAL-HEALTH; ALOPECIA-AREATA; INCREASED RISK; BURDEN; PREVALENCE; ADULTS; IMPACT;
D O I
10.1097/DER.0000000000000841
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundPatients with atopic dermatitis (AD) are susceptible to infectious and inflammatory cutaneous comorbidities.ObjectiveThe aim of the study was to describe the prevalence of cutaneous comorbidities associated with AD, including their relationship with AD severity.MethodsA retrospective cross-sectional analysis was performed using the Israeli Maccabi Healthcare Services database. Prevalent AD cases on December 31, 2017, were diagnosed with AD at any time since 1998 and had 1 or more recent (2013-2017) AD diagnoses. Dispensed AD treatments within 5 or fewer years served as a surrogate for AD severity. Cutaneous comorbidities in AD cases were compared with non-AD controls matched 1:1 on age, sex, and residential area. Among adults, comorbidities were compared across AD severity using multinomial logistic regression.ResultsThe eligible population included 94,483 patients with mild (57.7%), moderate (36.2%), or severe (6.1%) AD, and 94,483 matched non-AD controls. Skin infections, inflammatory skin conditions, cutaneous manifestations of AD, and sweat gland disorders were more prevalent (P < 0.001) in patients with AD than in controls. Most cutaneous comorbidities that were more prevalent in adult patients with AD were also significantly (P < 0.001) associated with AD severity.ConclusionsThis study suggests that AD is associated with many infectious and inflammatory cutaneous comorbidities and highlights the relationship between AD severity and comorbidity prevalence.
引用
收藏
页码:S61 / S68
页数:8
相关论文
共 50 条
[41]   Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study [J].
Hu, Yu-Qing ;
Zhang, Jian-Zhong ;
Zhao, Yan .
DERMATOLOGY, 2024, 240 (04) :589-596
[42]   Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis [J].
Olydam, J. I. ;
Schloesser, A. R. ;
Custurone, P. ;
Nijsten, T. E. C. ;
Hijnen, D. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (12) :2537-2542
[43]   Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort [J].
Schloesser, Anne R. ;
Boeijink, Neill ;
Olydam, Jill ;
Nijsten, Tamar E. C. ;
Hijnen, Dirkjan .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (02) :384-392
[44]   Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis [J].
Chester, Johanna ;
Kaleci, Shaniko ;
Liberati, Serena ;
Alicandro, Tatiana ;
Rivi, Marco ;
Bonzano, Laura ;
Guanti, Mario ;
Andreone, Pietro ;
Pellacani, Giovanni .
EUROPEAN JOURNAL OF DERMATOLOGY, 2022, 32 (01) :34-48
[45]   Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study [J].
Gargiulo, L. ;
Ibba, L. ;
Piscazzi, F. ;
Alfano, A. ;
Ingurgio, R. Cascio ;
Valenti, M. ;
Costanzo, A. ;
Narcisi, A. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (02) :e152-e154
[46]   Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study [J].
Ibba, Luciano ;
Falcidia, Costanza ;
Di Giulio, Sara ;
Bianco, Matteo ;
Valenti, Mario ;
Facheris, Paola ;
Narcisi, Alessandra ;
Costanzo, Antonio ;
Gargiulo, Luigi .
JOURNAL OF CLINICAL MEDICINE, 2025, 14 (09)
[47]   Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis [J].
Wu, Jashin J. ;
Lafeuille, Marie-Helene ;
Emond, Bruno ;
Fakih, Iman ;
Duh, Mei Sheng ;
Cappelleri, Joseph C. ;
Yin, Natalie ;
Feeney, Claire ;
Myers, Daniela E. ;
DiBonaventura, Marco .
ADVANCES IN THERAPY, 2022, 39 (09) :4157-4168
[48]   Real-world effectiveness and safety of abrocitinib in 12 Japanese patients with atopic dermatitis and transcriptome analysis with peripheral blood [J].
Uchiyama, Akihiko ;
Kosaka, Keiji ;
Ishikawa, Mai ;
Inoue, Yuta ;
Motegi, Sei-ichiro .
JOURNAL OF DERMATOLOGY, 2024, 51 (06) :849-853
[49]   One-Year Effectiveness and Safety of Dupilumab Treatment for Moderate- to-Severe Atopic Dermatitis in Korean Patients: A Real-World Retrospective Analysis [J].
Lee, Hanjae ;
Kim, Bo Ri ;
Kim, Kyu Han ;
Lee, Dong Hun ;
Na, Jung Im .
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2022, 14 (01) :117-122
[50]   Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data [J].
Marcellusi, A. ;
Mennini, F. S. ;
Sciattella, P. ;
Favato, G. .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2021, 22 (09) :1371-1379